Recursion Pharmaceuticals Reports 33% Revenue Jump in Q2 2025, Highlighting AI-Driven Drug Discovery Progress

Financial Performance and Challenges

Recursion Pharmaceuticals (NASDAQ: RXRX), a technology-driven biotech company, reported a significant 33% increase in revenue for the second quarter of 2025. The company's GAAP revenue reached $19.3 million, surpassing analyst expectations of $15.5 million 1

1

. This impressive growth was largely attributed to collaboration milestones, including a $7 million milestone payment from Sanofi 2

2

.

Despite the revenue boost, Recursion faced challenges with increased expenses. Research and development costs surged by 74% year-over-year, influenced by the integration of Exscientia (acquired in late 2024) and higher platform and collaboration costs 1

1

. This led to a larger net loss of $171.3 million (GAAP), compared to $97.5 million in the same period last year 1

1

.

AI-Driven Drug Discovery Platform

At the heart of Recursion's operations is its Recursion Operating System (Recursion OS), a full-stack platform leveraging artificial intelligence, automation, and extensive biological datasets to accelerate drug discovery 1

1

. The company recently rolled out Recursion OS 2.0, an upgraded version that integrates Exscientia's AI-driven chemistry capabilities and large-scale multimodal clinical datasets from partners such as Tempus, HealthVerity, and Helix 1

1

.

Chris Gibson, Co-Founder and CEO of Recursion, emphasized the power of their platform: "The power of our platform not only allows us to discover and develop potential new medicines but also gives us insights on patient populations to target that would be challenging using traditional methods" 2

2

.

Strategic Partnerships and Milestones

Recursion's business model heavily relies on partnerships with major pharmaceutical companies. The collaboration with Sanofi has been particularly fruitful, with the recent milestone payment bringing the total received from Sanofi to $130 million as of Q2 2025 1

1

. Other notable partnerships include those with Roche, Genentech, Bayer, and Merck KGaA, focusing on various areas such as neurology, oncology, and generating large biological datasets 1

1

.

The company estimates that partnership milestones due by the end of 2026 could exceed $100 million, although the timing remains uncertain 1

1

.

Pipeline Progress and Clinical Trials

Recursion's pipeline showed significant advancements in several key areas:

1. REC-617 (CDK7 inhibitor): Showing promise in treating ovarian and other cancers 1

   1

   .
2. REC-1245 (RBM39 degrader): Demonstrating strong activity in tumors characterized by replication stress and DNA repair vulnerabilities 2

   2

   .
3. REC-4881 (MEK1/2 inhibitor): Advancing in the treatment of familial adenomatous polyposis 1

   1

   .
4. REC-102 (ENPP1 inhibitor): Planned for Phase 1 initiation in the second half of 2026 for the rare disease hypophosphatasia 1

   1

   .

Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer of Recursion, highlighted the company's data-driven approach: "We leveraged multi-omic and real-world patient data and causal AI modeling to select platinum-resistant ovarian cancer as the first combination cohort for REC-617" 2

2

.

Future Outlook and Cash Position

As of June 30, 2025, Recursion reported cash reserves of $533.3 million 1

1

. The company projects that its current cash runway will extend into the fourth quarter of 2027, assuming steady operating plans and continued partnership funding 1

1

. Management forecasts full-year 2025 cash burn at or below $450 million, excluding partnering or financing inflows 1

1

.

While Recursion's innovative approach to drug discovery shows promise, the company's reliance on milestone-based revenue from collaborations introduces an element of unpredictability to its financial future. The success of its AI-driven platform in translating scientific advancements into commercially viable drugs will be crucial for the company's long-term sustainability in the competitive biotech landscape.